Biologically Active Peptides from Venoms: Applications in Antibiotic Resistance, Cancer, and Beyond

Lucía Ageitos, Marcelo D. T. Torres, César de la Fuente‐NúñezInternational Journal of Molecular Sciences 2022 · DOI

TL;DR

Venoms, long feared for their toxicity, are a treasure trove of peptides with potent therapeutic potential against antibiotic resistance and cancer. This review highlights South American venomous organisms as a rich source of these peptides, detailing their diverse biological activities and potential applications in medicine.

What Problem Does This Paper Address?

The paper addresses the urgent need for novel therapeutic agents, particularly in the face of rising antibiotic resistance and the persistent challenge of cancer treatment. Existing treatments often come with significant side effects and diminishing effectiveness. The authors highlight that while venoms are known for their toxicity, they also contain a vast array of bioactive peptides that have evolved to target specific biological processes in prey. The challenge lies in identifying, characterizing, and harnessing these peptides for therapeutic benefit, especially given the low yields and complex purification processes involved. This review aims to consolidate knowledge on venom-derived peptides from South American organisms, showcasing their potential to fill this therapeutic gap.

Methods

This paper is a review, so it doesn't present novel experimental methods. Instead, it synthesizes information from existing research. The authors draw upon:

  • Bioanalytical technologies: Advances in these technologies have been crucial for identifying and characterizing venom components.
  • Genomics and Transcriptomics: These fields have enabled a deeper understanding of the genetic basis and expression of venom peptides.
  • Computational Biology: In silico approaches are increasingly used for peptide design, optimization, and prediction of activity.
  • Structure-Activity Relationship Studies: The review discusses how the physicochemical properties (charge, hydrophobicity, etc.) and structural features (e.g., disulfide bridges, alpha-helices, beta-sheets) of peptides dictate their biological activity and target interactions.
  • Preclinical and Clinical Data: The authors review studies demonstrating the efficacy of these peptides in animal models and their progression into clinical trials.

Datasets

Not applicable. This is a review article summarizing existing research and does not introduce new datasets or benchmarks.

Key Insights and Ideas

  • Venoms as a "Drug Discovery Platform": Venoms, despite their dangerous reputation, are highly evolved biological "toolkits" containing peptides with precise biological functions. This makes them an excellent starting point for discovering novel therapeutic agents.
  • South America as a Hotspot: Organisms from South America, including snakes, spiders, and scorpions, are particularly rich sources of diverse and potent venom-derived peptides with significant therapeutic potential.
  • Beyond Antimicrobials: While antimicrobial peptides (AMPs) are a major focus, venoms also yield peptides with anticancer, analgesic, anti-inflammatory, and other valuable properties.
  • Targeting Specificity: The evolution of venom peptides has led to high specificity for their targets (e.g., ion channels, receptors), which is a desirable trait for therapeutic drugs, minimizing off-target effects.
  • Structure Dictates Function: The specific 3D structure of venom peptides, often stabilized by disulfide bridges, is critical for their interaction with biological targets and their therapeutic efficacy.
  • Scaffolds for Rational Design: Venom peptides can serve as excellent templates for designing new, optimized therapeutic agents with improved potency, selectivity, and reduced toxicity.

Key Results

The review highlights numerous venom-derived peptides with promising activities:

  • Antimicrobial Activity: Peptides like Crotamine (from rattlesnake venom) show antifungal activity and are being explored for their cell-penetrating properties to target cancer cells. Polybia-CP (from wasp venom) demonstrates antimicrobial and antichagasic activity.
  • Anticancer Activity: Several peptides, including Crotamine and Crotalicidin, have shown cytotoxic effects against cancer cells.
  • Pain Management (Antinociception): Peptides from spiders, particularly Phoneutria nigriventer (armed spider), and tarantulas like Psalmotoxin 1 (PcTx1), are potent inhibitors of ion channels involved in pain signaling, showing promise for treating chronic and neuropathic pain.
  • Cardiovascular Applications: Peptides derived from snake venoms, such as Captopril and Enalapril (originally inspired by bradykinin-potentiating peptides), are already established drugs for hypertension and cardiac failure. Batroxobin is used for its defibrinogenating effect.
  • Preclinical and Clinical Progress: Several venom-derived peptides are in preclinical development or clinical trials, particularly for pain management (e.g., PcTx-1, JNJ63955918, GpTx-1).

Limitations and Future Work

  • Challenges in Production and Purification: The authors acknowledge that the low yield of peptides from venomous animals and the complexity of purification processes remain significant hurdles for large-scale therapeutic development.
  • Toxicity and Off-Target Effects: While many peptides show high specificity, some can still exhibit cytotoxicity or hemolytic activity, requiring careful optimization and formulation.
  • Need for Further Preclinical and Clinical Validation: Despite promising preclinical results, many venom-derived peptides require extensive further testing to establish their safety and efficacy in humans.
  • Future Directions: The authors emphasize the potential of rational design and computational methods to accelerate the discovery and optimization of venom-derived peptides. They also point to the exploration of synergistic activities between venom peptides and existing drugs as a promising avenue for combating drug resistance and enhancing treatment efficacy. The continued exploration of South American biodiversity for novel venom components is also highlighted as a key area for future research.

Summary updated

Abstract

Peptides are potential therapeutic alternatives against global diseases, such as antimicrobial-resistant infections and cancer. Venoms are a rich source of bioactive peptides that have evolved over time to act on specific targets of the prey. Peptides are one of the main components responsible for the biological activity and toxicity of venoms. South American organisms such as scorpions, snakes, and spiders are important producers of a myriad of peptides with different biological activities. In this review, we report the main venom-derived peptide families produced from South American organisms and their corresponding activities and biological targets.
BibTeX
@article{ageitos2022biologically,
  author = {Lucía Ageitos and Marcelo D. T. Torres and César de la Fuente‐Núñez},
  title = {{Biologically Active Peptides from Venoms: Applications in Antibiotic Resistance, Cancer, and Beyond}},
  journal = {International Journal of Molecular Sciences},
  year = {2022},
  doi = {10.3390/ijms232315437},
}

Loading related content...

Figure